147 related articles for article (PubMed ID: 31977312)
41. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats.
Durak A; Olgar Y; Degirmenci S; Akkus E; Tuncay E; Turan B
Cardiovasc Diabetol; 2018 Nov; 17(1):144. PubMed ID: 30447687
[TBL] [Abstract][Full Text] [Related]
42. Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion.
Vergari E; Knudsen JG; Ramracheya R; Salehi A; Zhang Q; Adam J; Asterholm IW; Benrick A; Briant LJB; Chibalina MV; Gribble FM; Hamilton A; Hastoy B; Reimann F; Rorsman NJG; Spiliotis II; Tarasov A; Wu Y; Ashcroft FM; Rorsman P
Nat Commun; 2019 Jan; 10(1):139. PubMed ID: 30635569
[TBL] [Abstract][Full Text] [Related]
43. Dapagliflozin attenuates renal gluconeogenic enzyme expression in obese rats.
Swe MT; Thongnak L; Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Lungkaphin A
J Endocrinol; 2020 May; 245(2):193-205. PubMed ID: 32092034
[TBL] [Abstract][Full Text] [Related]
44. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
Demaris KM; White JR
Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409
[TBL] [Abstract][Full Text] [Related]
45. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
[TBL] [Abstract][Full Text] [Related]
46. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
Chen H; Tran D; Yang HC; Nylander S; Birnbaum Y; Ye Y
Cardiovasc Drugs Ther; 2020 Aug; 34(4):443-461. PubMed ID: 32335797
[TBL] [Abstract][Full Text] [Related]
47. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
[TBL] [Abstract][Full Text] [Related]
48. [Dapagliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, Acutely Reduces Energy Expenditure in Brown Adipose Tissue via Neural Signals in Mice].
Chiba Y; Yamada T; Katagiri H
Yakugaku Zasshi; 2018; 138(7):945-954. PubMed ID: 29962474
[TBL] [Abstract][Full Text] [Related]
49. Effects of sodium-glucose cotransporter 2 inhibitor (dapagliflozin) on food intake and plasma fibroblast growth factor 21 levels in type 2 diabetes patients.
Kosugi R; Nakatani E; Okamoto K; Aoshima S; Arai H; Inoue T
Endocr J; 2019 Aug; 66(8):677-682. PubMed ID: 31130574
[TBL] [Abstract][Full Text] [Related]
50. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.
Ott C; Jumar A; Striepe K; Friedrich S; Karg MV; Bramlage P; Schmieder RE
Cardiovasc Diabetol; 2017 Feb; 16(1):26. PubMed ID: 28231831
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of Mitiglinide Combined with Dapagliflozin in Streptozotocin-nicotinamide-induced Type 2 Diabetic Rats and in Zucker Fatty Rats.
Akahane K; Inoue T; Yokoyama A; Yaguchi A; Ojima K; Kiguchi S; Maruyama K; Kobayashi M; Mori Y
Drug Res (Stuttg); 2015 Aug; 65(8):416-21. PubMed ID: 25188606
[TBL] [Abstract][Full Text] [Related]
52. Dapagliflozin Aggravates Renal Injury via Promoting Gluconeogenesis in db/db Mice.
Jia Y; He J; Wang L; Su L; Lei L; Huang W; Geng X; Zhang S; Meng X; Zhou H; Yang B
Cell Physiol Biochem; 2018; 45(5):1747-1758. PubMed ID: 29495021
[TBL] [Abstract][Full Text] [Related]
53. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
[TBL] [Abstract][Full Text] [Related]
54. Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.
Terasaki M; Hiromura M; Mori Y; Kohashi K; Nagashima M; Kushima H; Watanabe T; Hirano T
PLoS One; 2015; 10(11):e0143396. PubMed ID: 26606676
[TBL] [Abstract][Full Text] [Related]
55. Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice.
Omori K; Nakamura A; Miyoshi H; Takahashi K; Kitao N; Nomoto H; Kameda H; Cho KY; Takagi R; Hatanaka KC; Terauchi Y; Atsumi T
Metabolism; 2019 Sep; 98():27-36. PubMed ID: 31202833
[TBL] [Abstract][Full Text] [Related]
56. Melatonin ameliorates SGLT2 inhibitor-induced diabetic ketoacidosis by inhibiting lipolysis and hepatic ketogenesis in type 2 diabetic mice.
Park JH; Seo I; Shim HM; Cho H
J Pineal Res; 2020 Mar; 68(2):e12623. PubMed ID: 31743484
[TBL] [Abstract][Full Text] [Related]
57. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
58. Chronopharmacology of dapagliflozin-induced antihyperglycemic effects in C57BL/6J mice.
Yoshioka H; Ohishi R; Hirose Y; Torii-Goto A; Park SJ; Miura N; Yoshikawa M
Obes Res Clin Pract; 2019; 13(5):505-510. PubMed ID: 31466832
[TBL] [Abstract][Full Text] [Related]
59. Dapagliflozin: glucuretic action and beyond.
Balakumar P; Sundram K; Dhanaraj SA
Pharmacol Res; 2014 Apr; 82():34-9. PubMed ID: 24705156
[TBL] [Abstract][Full Text] [Related]
60. Effect of dapagliflozin on colon cancer cell [Rapid Communication].
Saito T; Okada S; Yamada E; Shimoda Y; Osaki A; Tagaya Y; Shibusawa R; Okada J; Yamada M
Endocr J; 2015; 62(12):1133-7. PubMed ID: 26522271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
